Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacolin is a small molecule drug candidate developed by the Institute of Materia Medica, Chinese Academy of Medical Sciences (IMM CAMS) for the treatment of Parkinson's disease. Classified as a Class 1.1 innovative drug in China, Bacolin is a flavonoid derivative designed to target multiple pathological pathways of the disease. Its primary mechanism of action involves the inhibition of alpha-synuclein aggregation, which is a hallmark of Parkinson's disease pathology. Additionally, it demonstrates neuroprotective effects through antioxidant and anti-inflammatory activities. Bacolin is currently in Phase 1 clinical development, with studies focusing on its safety, tolerability, and pharmacokinetic profile in healthy volunteers and elderly populations in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacolin.